Antje Danielczyk

Dermapharm (Germany) — Germany

Medicine · Health Sciences

11h-index509citations40works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(26), Glycosylation and Glycoproteins Research(21), Lung Cancer Treatments and Mutations(8), Galectins and Cancer Biology(8), HER2/EGFR in Cancer Research(7)

Publications40 total

Abstract 3429: Improving druggability of a promising tumor target by the novel glycosylation-dependent mAb GT-008 for treatment of solid tumors
Cancer Research·2025
Abstract 5896: Platform approach to develop antibodies specifically recognizing cancer-associated glycoforms
Cancer Research·2024
GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies
International Journal of Molecular Sciences·2024· 6 citedOpen Access
Targeting a cancer-specific LYPD3 glycoform for tumor therapy
Frontiers in Drug Discovery·2023· 2 citedOpen Access
1462 Antibodies specifically recognizing cancer-associated glycoforms of mucin-like proteins
Regular and Young Investigator Award Abstracts·2023Open Access
Abstract 1588: Using glyco-engineered cells with flexible expression of tumor-associated carbohydrates for the generation of highly tumor-specific antibodies
Cancer Research·2023
Supplementary Table 1 and 2 from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Supplemental Figures 1 to 6 from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Supplemental Figures 1 to 6 from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Supplementary Figure Legends from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Data from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Supplementary Figure Legends from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Supplementary Table 1 and 2 from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Data from Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> Polymorphism
2023Open Access
Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems
International Journal of Molecular Sciences·2022· 8 citedOpen Access
1347 Targeting of a cancer-associated LYPD3 glycoform for tumor therapy
Regular and Young Investigator Award Abstracts·2022· 3 citedOpen Access
1346 Antibodies against GlycoTargets as novel platform approach to address unmet needs in cancer therapy
Regular and Young Investigator Award Abstracts·2022· 1 citedOpen Access
Abstract 2879: Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties
Cancer Research·2022
Abstract 316: Carbohydrate-dependent protein binding antibodies with superior tumor-specificity
Cancer Research·2022· 1 cited
781 GT-001 - anti-Lewis Y antibody with superior fine-specificity and reduced off-target binding
Regular and Young Investigator Award Abstracts·2021· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Steffen Goletz(26), Johanna Gellert(12), Patrik Kehler(12), Beate Habel(10), Timo Lischke(10), Uwe Karsten(9), Friederike Braig(9), Malte Kriegs(9), Minna Voigtlaender(9), Tobias Grob(9), Karina Biskup(9), Véronique Blanchard(9), M. Sack(9), Anja Thalhammer(9), Isabel Ben‐Batalla(9), Ingke Braren(9), Simon Laban(9), Elżbieta Jakubowicz(9), Bruno Märkl(9), Martin Trepel(9)